Tocopherol (vitamin E) in Alzheimer's disease and other neurodegenerative disorders.

Abstract:

:In this article, we review the evidence that tocopherol (vitamin E) may have a role to play in the prevention and treatment of Alzheimer's disease and other neurological diseases. The theoretical rationale for the effectiveness of tocopherol as treatment and/or prevention of Alzheimer's disease is based on its antioxidant properties. Results from animal and in vitro studies provide evidence to support use of tocopherol for prevention and treatment of degenerative neurological diseases. Furthermore, several, but not all, epidemiological, cross-sectional, prospective studies indicate that tocopherol may have protective effects in Alzheimer's disease, although dietary and supplemental forms of the vitamin may differ in their efficacy. Mixed results have been obtained from clinical trials. Evidence of the use of tocopherol as a protective measure or as therapy in neurological diseases other than Alzheimer's disease is less compelling. To date, there are no clear-cut answers as to whether tocopherol is worth prescribing, but current clinical practice favours its use in the treatment of Alzheimer's disease.

journal_name

CNS Drugs

journal_title

CNS drugs

authors

Berman K,Brodaty H

doi

10.2165/00023210-200418120-00005

subject

Has Abstract

pub_date

2004-01-01 00:00:00

pages

807-25

issue

12

eissn

1172-7047

issn

1179-1934

pii

18125

journal_volume

18

pub_type

杂志文章,评审
  • A Retrospective Cohort Study of Acute Kidney Injury Risk Associated with Antipsychotics.

    abstract:BACKGROUND:A recent large database analysis raised concerns of potential acute kidney injury (AKI) risk associated with antipsychotics. However, whether individual atypical and typical antipsychotics are associated with differential AKI risks has not been investigated. OBJECTIVE:The current study compared the risks of...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-017-0421-4

    authors: Jiang Y,McCombs JS,Park SH

    更新日期:2017-04-01 00:00:00

  • Fatalities associated with therapeutic use and overdose of atypical antipsychotics.

    abstract::Since 1989, several novel antipsychotic drugs have become available for use including clozapine, risperidone, olanzapine, quetiapine and ziprasidone. These agents represent a substantial improvement in the treatment of schizophrenia and related disorders and are considered to have a favourable adverse effect profile r...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200317050-00002

    authors: Trenton A,Currier G,Zwemer F

    更新日期:2003-01-01 00:00:00

  • Mixed Anxiety and Depression : Diagnosis and Treatment Options.

    abstract::Symptoms of anxiety and depression often appear together in patients, either as 2 discrete disorders, such as major depressive disorder and panic disorder, or as a combination of symptoms not meeting criteria for specific disorders. The social, economic, occupational and medical costs of such comorbid anxiety and depr...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.2165/00023210-199809040-00003

    authors: Bakish D,Habib R,Hooper CL

    更新日期:1998-04-01 00:00:00

  • A naturalistic study of galantamine for Alzheimer's disease.

    abstract:OBJECTIVE:To collect descriptive data on the treatment of Alzheimer's disease with galantamine under naturalistic conditions. STUDY DESIGN:This was a prospective, open-label, observational study. PATIENTS:Subjects (n = 345) with mild to moderately severe dementia of the Alzheimer's type were recruited from 48 hospita...

    journal_title:CNS drugs

    pub_type: 临床试验,杂志文章

    doi:10.2165/00023210-200620110-00006

    authors: Brodaty H,Woodward M,Boundy K,Barnes N,Allen G,NATURE Investigators.

    更新日期:2006-01-01 00:00:00

  • Overview of the therapeutic management of insomnia with zolpidem.

    abstract::Benzodiazepine hypnotic agents were the mainstream pharmacotherapy for insomnia from the 1960s to the 1980s, but their safety profile proved to be not quite as perfect as originally expected with regard to daytime performance and cognition, and above all the risk of dependence. These risks are substantially diminished...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200418001-00005

    authors: Lee YJ

    更新日期:2004-01-01 00:00:00

  • Overview of Current Drug Delivery Methods Across the Blood-Brain Barrier for the Treatment of Primary Brain Tumors.

    abstract::Existing drug delivery methods have not led to a significant increase in survival for patients with malignant primary brain tumors. While the combination of conventional therapies consisting of surgery, radiotherapy, and chemotherapy has improved survival for some types of brain tumors (e.g., WNT medulloblastoma), oth...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-020-00766-w

    authors: Haumann R,Videira JC,Kaspers GJL,van Vuurden DG,Hulleman E

    更新日期:2020-11-01 00:00:00

  • Antipsychotic polypharmacy in schizophrenia: benefits and risks.

    abstract::Antipsychotic polypharmacy refers to the co-prescription of more than one antipsychotic drug for an individual patient. Surveys of prescribing in psychiatric services internationally have identified the relatively frequent and consistent use of combined antipsychotics, usually for people with established schizophrenia...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11587810-000000000-00000

    authors: Barnes TR,Paton C

    更新日期:2011-05-01 00:00:00

  • Pharmacological interventions for the treatment of smokeless tobacco use.

    abstract::Smokeless tobacco (SLT) is used in a variety of forms throughout the world. Long-term SLT use is associated with adverse health consequences. Effective pharmacotherapies are needed to treat SLT users who want to achieve tobacco abstinence. In the current review, we discuss the pharmacological interventions identified ...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11598450-000000000-00000

    authors: Ebbert JO,Fagerstrom K

    更新日期:2012-01-01 00:00:00

  • Restoring Function to Dopaminergic Neurons: Progress in the Development of Cell-Based Therapies for Parkinson's Disease.

    abstract::There is escalating interest in cell-based therapies to restore lost dopamine inputs in Parkinson's disease. This is based upon the rationale that implanting dopamine progenitors into the striatum can potentially improve dopamine-responsive motor symptoms. A rich body of data describing clinical trials of previous cel...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-020-00727-3

    authors: Henchcliffe C,Sarva H

    更新日期:2020-06-01 00:00:00

  • Does pharmacological treatment of ADHD in adults enhance parenting performance? Results of a double-blind randomized trial.

    abstract:OBJECTIVE:This study examines the effects of parental lisdexamfetamine (LDX) treatment on parent-child interactions. METHODS:Participants were 30 parents (27% were male) and their children aged 5-12 years, both diagnosed with DSM-IV attention-deficit/hyperactivity disorder (ADHD). Optimal LDX dose (30, 50, or 70 mg/da...

    journal_title:CNS drugs

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s40263-014-0165-3

    authors: Waxmonsky JG,Waschbusch DA,Babinski DE,Humphrey HH,Alfonso A,Crum KI,Bernstein M,Slavec J,Augustus JN,Pelham WE

    更新日期:2014-07-01 00:00:00

  • Taming glutamate excitotoxicity: strategic pathway modulation for neuroprotection.

    abstract::Much work has been carried out in recent years showing that elevated glutamate levels in the extracellular environment of the central nervous system play a pivotal role in neurodegeneration in acute CNS injuries. With the elucidation of the mechanism governing glutamate excitotoxicity, researchers are devising therape...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-015-0225-3

    authors: Jia M,Njapo SA,Rastogi V,Hedna VS

    更新日期:2015-02-01 00:00:00

  • Blonanserin: a review of its use in the management of schizophrenia.

    abstract::Oral blonanserin (Lonasen) is an atypical antipsychotic agent indicated for use in patients with schizophrenia in Japan and Korea. It is effective in the treatment of patients with schizophrenia, providing short- and long-term efficacy against both the positive and negative symptoms of the disorder in several randomiz...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11202620-000000000-00000

    authors: Deeks ED,Keating GM

    更新日期:2010-01-01 00:00:00

  • The Female Sexual Response: Current Models, Neurobiological Underpinnings and Agents Currently Approved or Under Investigation for the Treatment of Hypoactive Sexual Desire Disorder.

    abstract::How a woman responds to sexual cues is highly dependent on a number of distinct, yet related, factors. Researchers have attempted to explain the female sexual response for decades, but no single model reigns supreme. Proper female sexual function relies on the interplay of somatic, psychosocial and neurobiological fac...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-015-0288-1

    authors: Kingsberg SA,Clayton AH,Pfaus JG

    更新日期:2015-11-01 00:00:00

  • Pharmacological management of neuropathic pain following spinal cord injury.

    abstract::Spinal cord injury (SCI) has a number of severe and disabling consequences, including chronic pain, and around 40% of patients develop persistent neuropathic pain. Pain following SCI has a detrimental impact on the patient's quality of life and is a major specific healthcare problem in its own right. Thus far, there i...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200822060-00002

    authors: Baastrup C,Finnerup NB

    更新日期:2008-01-01 00:00:00

  • Cost effectiveness of pharmacotherapy for the prevention of migraine: a Markov model application.

    abstract:BACKGROUND:There are few data about the cost effectiveness of prophylactic medications for migraine. Clinical trials have shown several preventive agents to be useful in reducing the frequency of migraine attack while having tolerable side effects. OBJECTIVE:To compare the cost effectiveness of adding preventive treat...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.2165/11531180-000000000-00000

    authors: Yu J,Smith KJ,Brixner DI

    更新日期:2010-08-01 00:00:00

  • The Therapeutic Role of Gangliosides in Neurological Disorders.

    abstract::Numerous in vitro and in vivo experimental animal studies have demonstrated that gangliosides, particularly GMI ganglioside (siagoside), may stimulate or accelerate the repair of peripheral and central nervous system neurons after various types of damage. Clinical studies of GMl in peripheral neuropathies and stroke, ...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.2165/00023210-199401030-00006

    authors: Schneider JS

    更新日期:1994-03-01 00:00:00

  • Rapid improvement of chronic stroke deficits after perispinal etanercept: three consecutive cases.

    abstract:BACKGROUND:Thrombolytic therapy reduces stroke size and disability by reperfusion and salvage of ischaemic penumbra. Emerging evidence suggests that retrieved penumbra may be the site of ongoing inflammatory pathology that includes extensive microglial activation. Microglial activation may be associated with excessive ...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.2165/11588400-000000000-00000

    authors: Tobinick E

    更新日期:2011-02-01 00:00:00

  • Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes.

    abstract::Biopharmaceuticals can induce antibodies, which interact with and neutralize the therapeutic effect of such drugs and are therefore termed neutralizing antibodies (NAbs). In the treatment of multiple sclerosis, NAbs against interferon (IFN)-beta and natalizumab have been recognized. The prevalence of NAbs against diff...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200923050-00003

    authors: Deisenhammer F

    更新日期:2009-01-01 00:00:00

  • Anticonvulsants for the treatment of alcohol withdrawal syndrome and alcohol use disorders.

    abstract::Alcoholic patients suffer from harmful allostatic neuroplastic changes in the brain causing an acute withdrawal syndrome upon cessation of drinking followed by a protracted abstinence syndrome and an increased risk of relapse to heavy drinking. Benzodiazepines have long been the treatment of choice for detoxifying pat...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-015-0240-4

    authors: Hammond CJ,Niciu MJ,Drew S,Arias AJ

    更新日期:2015-04-01 00:00:00

  • The new generation of GABA enhancers. Potential in the treatment of epilepsy.

    abstract::gamma-Aminobutyric acid (GABA) is considered to be the major inhibitory neurotransmitter in the brain and loss of GABA inhibition has been clearly implicated in epileptogenesis. GABA interacts with 3 types of receptor: GABAA, GABAB and GABAC. The GABAA receptor has provided an excellent target for the development of d...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200115050-00001

    authors: Czuczwar SJ,Patsalos PN

    更新日期:2001-01-01 00:00:00

  • A Decade of Gabapentinoid Misuse: An Analysis of the European Medicines Agency's 'Suspected Adverse Drug Reactions' Database.

    abstract:INTRODUCTION:The gabapentinoids pregabalin and gabapentin are being increasingly prescribed for a range of clinical conditions. Recently, although gabapentinoids at therapeutic dosages may present with low addictive liability levels, cases of misuse and rising numbers of related fatalities have been reported. OBJECTIV...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-016-0359-y

    authors: Chiappini S,Schifano F

    更新日期:2016-07-01 00:00:00

  • Treating depression in children and adolescents: what options now?

    abstract::There have been significant developments in the understanding of depression in children and adolescents in the past few years, including an increased recognition that significant depressive illness occurs in this patient group. Pharmacological and psychotherapeutic treatments are used to manage depression in children ...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200620010-00001

    authors: Varley CK

    更新日期:2006-01-01 00:00:00

  • Spotlight on levetiracetam in epilepsy.

    abstract::Levetiracetam (Keppra®, E Keppra®) is an established second-generation antiepileptic drug (AED). Worldwide, levetiracetam is most commonly approved as adjunctive treatment of partial-onset seizures with or without secondary generalization; other approved indications include monotherapy treatment of partial-onset seizu...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11208340-000000000-00000

    authors: Lyseng-Williamson KA

    更新日期:2011-10-01 00:00:00

  • HIV-related movement disorders: epidemiology, pathogenesis and management.

    abstract::Clinically relevant movement disorders are identified in 3% of patients with HIV infection seen at tertiary referral centres. In the same setting, prospective follow-up shows that 50% of patients with AIDS develop tremor, parkinsonism or other extrapyramidal features. Hemiballism-hemichorea and tremor are the most com...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200216100-00002

    authors: Cardoso F

    更新日期:2002-01-01 00:00:00

  • Correlates of Clozapine Use after a First Episode of Schizophrenia: Results From a Long-term Prospective Study.

    abstract:BACKGROUND:Earlier commencement of clozapine has been related to a better response in treatment-resistant schizophrenia. OBJECTIVES:To identify variables that predict clozapine use after a first episode of schizophrenia (FES). METHODS:Patients with FES and ≤15 days of lifetime antipsychotic treatment were followed up...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-016-0358-z

    authors: Üçok A,Çıkrıkçılı U,Ergül C,Tabak Ö,Salaj A,Karabulut S,Correll CU

    更新日期:2016-10-01 00:00:00

  • Therapeutic Potential of Ursolic Acid to Manage Neurodegenerative and Psychiatric Diseases.

    abstract::Ursolic acid is a pentacyclic triterpenoid found in several plants. Despite its initial use as a pharmacologically inactive emulsifier in pharmaceutical, cosmetic and food industries, several biological activities have been reported for this compound so far, including anti-tumoural, anti-diabetic, cardioprotective and...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-017-0474-4

    authors: Ramos-Hryb AB,Pazini FL,Kaster MP,Rodrigues ALS

    更新日期:2017-12-01 00:00:00

  • Diclofenac potassium powder for oral solution: a review of its use in patients with acute migraine.

    abstract::Diclofenac potassium powder for oral solution (Voltfast(®), Catafast(®), Cambia(®); hereafter referred to as diclofenac potassium powder) is a non-steroidal anti-inflammatory drug (NSAID), and is indicated for the acute treatment of migraine. This article reviews the pharmacological properties of diclofenac potassium ...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-014-0186-y

    authors: Garnock-Jones KP

    更新日期:2014-08-01 00:00:00

  • Luteal phase administration of agents for the treatment of premenstrual dysphoric disorder.

    abstract::This review focuses on current information about luteal phase administration (i.e. typically for the last 2 weeks of the menstrual cycle) of pharmacological agents for the treatment of premenstrual dysphoric disorder (PMDD). Compared with continuous administration, a luteal phase administration regimen reduces the exp...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200418070-00004

    authors: Freeman EW

    更新日期:2004-01-01 00:00:00

  • Management of psychiatric comorbidity in anorexia nervosa and bulimia nervosa.

    abstract::The eating disorders anorexia nervosa and bulimia nervosa present with comorbidity in a number of important areas, including depression, bipolar disorder, anxiety disorders (obsessive-compulsive disorder, panic disorder, social anxiety disorder and other phobias, and post-traumatic stress disorder) and substance abuse...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200620080-00004

    authors: Woodside BD,Staab R

    更新日期:2006-01-01 00:00:00

  • Novel IDH1-Targeted Glioma Therapies.

    abstract::Mutations in the isocitrate dehydrogenase (IDH) 1 gene are commonly found in human glioma, with the majority of low-grade gliomas harboring a recurrent point mutation (IDH1 R132H). Mutant IDH reveals an altered enzymatic activity leading to the synthesis of 2-hydroxyglutarate, which has been implicated in epigenetic m...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-019-00684-6

    authors: Karpel-Massler G,Nguyen TTT,Shang E,Siegelin MD

    更新日期:2019-12-01 00:00:00